Experimental autoimmune encephalomyelitis (EAE) was induced in Lewis rats by inoculation with myelin basic protein (MBP) and adjuvants. Rats were treated with second daily injections of saline or cyclosporin A (CsA) from the day of inoculation. Saline-treated rats had an acute episode of disease followed by clinical recovery. Rats treated with CsA 16 or 32 mg/kg had minimal signs of EAE at the usual time after inoculation, but developed signs of disease after treatment was ceased. Rats treated with CsA 8 mg/kg had a delayed first episode of disease and then developed a relapsing or a chronic persistent course of disease. CsA 4 mg/kg delayed the onset of disease. To study the effects of CsA on the inflammatory infiltrate, cells were extracted from the spinal cords of rats with EAE, 16 h after a single injection of CsA or saline. Extracted cells were labelled with antibodies to T cells, CD11b/c (macrophages/microglia), CD95 (Fas) and Fas ligand. CsA 4 mg/kg did not alter the composition of the inflammatory infiltrate. Treatment with higher single doses of CsA caused a dose-dependent decline in the percentage of T cell receptor (TCR) + cells in the inflammatory infiltrate. All doses of CsA caused a significant increase in the number and percentage of cells that were apoptotic. CsA treatment caused an increase in the percentages of CD5 + and TCR + cells that were apoptotic. There was a decline in the percentage of apoptotic T cells that were V 8.2 + , compared to the percentage of nonapoptotic T cells that were V 8.2 + , in CsA treated rats compared to saline-treated controls. This suggests that, while CsA treatment caused a non-specific increase in the overall level of T cell apoptosis in the spinal cord, it abrogated the selective apoptosis of V 8.2 + encephalitogenic T cells that normally occurs during spontaneous recovery from acute EAE.
Introduction
Cyclosporin A (CsA) is a cyclic peptide with immunomodulatory properties. CsA acts within the cell by binding to cyclophilin, an immunophilin. This results in inactivation of calcineurin, and suppression of transcription of genes, including those for cytokines and cytokine receptors (Flanagan et al., 1991) . Immunophilins also have neuroprotective abilities (Sabatini et al., 1997) . CsA is used as an immunosuppressive agent in organ transplantation and in the treatment of autoimmune diseases. In multiple sclerosis, CsA treatment has been of modest benefit (Multiple Sclerosis Study Group, 1990) . In some situations, CsA can provoke autoimmune disease. One example of CsA-induced autoimmunity is the graft versus host disease that occurs in CsA-treated animals after syngeneic bone marrow transplantation (Hess et al., 1994) . CsA in high doses suppresses clinical signs of experimental autoimmune encephalomyelitis (EAE) (Bolton et al., 1982; Polman et al., 1988) which is an animal model of multiple sclerosis. In Lewis rats, treatment with low-dose CsA (4 mg/kg) converts EAE induced by inoculation with guinea pig spinal cord from an acute to a chronic relapsing disease (Polman et al., 1988; Pender et al., 1990; McCombe et al., 1994) . The relapsing disease produced by treatment with CsA may result from the suppression of the immunoregulatory mechanisms that normally prevent further episodes of disease. In EAE, such regulatory mechanisms may include suppressor cells (Karpus et al., 1992) , downregulatory cytokines, and apoptosis of T cells in the central nervous system (CNS) (Pender et al., 1991 and Pender et al., 1992; Schmied et al., 1993; Tabi et al., 1994 and Tabi et al., 1995; McCombe et al., 1996a ).
The present study was performed in two parts. Firstly, we assessed the effects of CsA treatment on the clinical course of EAE induced by inoculation with myelin basic protein (MBP), to determine whether this is similar to the effects of CsA on EAE induced by inoculation with whole spinal cord. Secondly, we studied the effects of a single dose of CsA on the inflammatory infiltrate extracted from the spinal cord of rats with EAE. Because apoptosis is involved in the spontaneous recovery of rats from acute EAE, we also assessed the effects of CsA on apoptosis of inflammatory cells in the spinal cord in EAE.
Methods

Induction of EAE
Male Lewis rats (JC strain), aged 8-10 weeks, were obtained from the Central Animal Breeding House of The University of Queensland. MBP was prepared from guinea pig brains by the method of Deibler et al. (1972) . MBP in 0.9% saline was emulsified in an equal volume of incomplete Freund's adjuvant containing 4 mg/ml Mycobacterium butyricum. On day 0, rats were inoculated in one hind footpad with 0.1 ml emulsion. The total dose of MBP was 50 µ g/rat. We assessed weakness of the tail, hindlimbs and forelimbs. The degree of weakness of each region was separately graded on a scale of 0 (no weakness) to 4 (total paralysis) as previously described (Pender, 1986) . The scores from each region were added together to give a total clinical score (maximum total clinical score=12).
CsA treatment
For studies of the effects of CsA treatment on the clinical course of EAE, rats were given intraperitoneal injections of saline or CsA every second day, commencing on the day of inoculation, for periods of 21-42 days. For studies of the effects of CsA on the cells extracted from the spinal cord, rats were given a single injection of CsA, at an interval of 16 h before sacrifice on either day 14 or day 15 after inoculation.
Extraction of cells from spinal cord
As described previously (McCombe et al., 1996b) , cells were isolated from the spinal cords of anaesthetized rats perfused with ice-cold saline. The spinal cord was removed by insufflation, weighed, and a single cell suspension in ice-cold RPMI 1640 containing 1% foetal calf serum (FCS) was prepared. The cell suspension was mixed with isotonic Percoll (Percoll: Hank's balanced salt solution 9:1) in a 3:2 ratio (density 1.052) in 50 ml centrifuge tubes and centrifuged for 25 min at 640×g at 4°C. The myelin layer and supernatant were discarded, while the last 9 ml supernatant and the cell pellet were retained. The cell pellet was resuspended, transferred to a conical 10 ml centrifuge tube, underlaid with 1 ml Ficoll and centrifuged for 20 min at 600×g at 4°C. Cells were harvested from the interface.
Antibodies
We used the following primary antibodies: OX19 (Dallman et al., 1984 ) (CD5); R73 (Hünig et al., 1989 ) (TCR ); R78 (Torres Nagel et al., 1993) which labels V 8.2 + T cells (the predominant encephalitogenic cells in MBP-EAE) (Imrich et al., 1995) ; OX42, which labels CD11b/c+ cells (macrophages and microglia); and rabbit polyclonal antibodies specific for rat CD95 (Fas) (Santa Cruz) and rat CD95 (Fas) ligand (Santa Cruz Biotechnology). The secondary antibodies were fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG F(ab′)2 (STAR 41) (Serotec) and FITCconjugated goat anti-rabbit IgG (ab′)2 (Rockland, Gilbertsville, PA).
Labelling of cells and flow cytometric analysis
Cells were labelled for flow cytometric analysis, using our previously described methods (McCombe et al., 1996b) . Aliquots of 105-106 cells were washed with a 1:1 solution of serum in phosphate-buffered saline (PBS) containing 1% FCS and 0.1% sodium azide, then incubated with primary antibodies in PBS/azide for 30 min at 4°C. Samples were washed and incubated with secondary antibody for 30 min at 4°C in the dark. Cells were washed twice with PBS and were resuspended in 1 ml of ice-cold 50% ethanol and fixed overnight at 4°C. The following day, the cells were washed in PBS. The cell pellets were resuspended in an appropriate volume (100-300 l) of propidium iodide (PI)-staining solution (freshly prepared by diluting stock solution [5 mg/ml RNase/250 g/ml PI in 0.1 M PBS), pH 7.4/0.1 mM EDTA] 1:4 with PBS/azide). Samples were kept on ice, in the dark, and analyzed using a Becton Dickinson FACScan. Flow cytometric data were analyzed using Lysis II Software (Becton Dickinson). The percentages of antibody-positive cells were determined from histograms of FITC fluorescence intensity. Background fluorescence, obtained by labelling the cells with isotype-control antibodies and FITC-conjugated secondary antibody, was subtracted from the test values. To analyze the proportions of cells undergoing apoptosis, or in G1/G0 or S/G2/M phase, histograms of PI fluorescence were obtained, as described by Telford et al. (1991) . Apoptotic events were defined as those having lower fluorescence than the sharply defined G0/G1 peak (White et al., 1998b) . Events with higher fluorescence than this peak were defined as being in S/G2/M phase. Events with a low level of red (PI) fluorescence were not collected. Electronic compensation for two-colour analysis ensured unchanged FITC distribution following PI labelling of DNA.
Statistical analysis
Statistical analysis was carried out using analysis of variance (ANOVA) with Sigmastat 2.0 (Jandel Scientific). Results for observations at different doses of CsA were then compared with results for saline by the Tukey test.
Results
Effect of second daily CsA treatment on the clinical course of EAE
A summary of the effects of CsA treatment is shown in Table 1 , and examples of the clinical course of individual rats are shown in Fig. 1 . Rats treated with saline for 21-42 days had a first episode of disease commencing around day 10. Some saline-treated rats had a second episode of disease, but none had a third episode of disease or chronic disease. Rats treated with CsA 4 mg/kg had a clinical course of disease similar to that of saline-treated rats, except that the onset of signs of disease was delayed. Second daily treatment with CsA 8 mg/kg caused a mild delay of the first episode of disease and then multiple relapses or a chronic persistent course of disease in 50% of the rats. In this group, rats in the first episode of disease generally had weakness of the tail and hindlimbs, while in the later episodes of disease there was weakness of the tail and forelimbs, but not the hindlimbs. Second daily treatment with CsA 16 or 32 mg/kg prevented the development of disease during the course of treatment, although the rats later developed signs of disease after CsA treatment was ceased. The rat treated with saline had a single episode of disease, the rat treated with CsA 8 mg/kg had a delayed onset of disease followed by relapses, while the rats treated with CsA 16 and 32 mg/kg failed to develop disease until treatment had been ceased.
Effect of a single dose of CsA on spinal cord inflammatory cells
The details of rats in the study are shown in Table 2 . A single dose of CsA had no significant effect on the severity of disease or on the number of cells extracted from the spinal cord, compared to treatment with saline. The proportions and numbers of cells of different types are shown in Table 3 . Treatment with CsA 4 mg/kg or 8 mg/kg had no significant effect on the composition of the cell population. 
Effect of a single dose of CsA on apoptosis
In the total cell population, treatment with 4 mg/kg (on day 14) did not alter the percentage of cells that were apoptotic (data not shown). Treatment with CsA 8, 16 or 32 mg/kg (on day 15) produced a significant, dose-dependent increase in the number and percentage of cells that were apoptotic (Fig. 2) . In a dose-dependent fashion, there was a significant increase in the percentage of cells that were apoptotic after CsA treatment, and an increase in the number of apoptotic cells, although this was only significant for the highest dose of CsA. The increase in the percentage of cells that were apoptotic was accompanied by a decrease in the percentage of cells that were in G0/G1 phase.
Effect of a single dose of CsA on selective apoptosis of V 8.2 + cells
There was no significant change in the number or percentage of V 8.2 + cells that were apoptotic, after a single injection of CsA (Table 4) (Tabi et al., 1994) . Similar selective apoptosis of V 8.2 + cells also occurs in the CNS in EAE induced by active immunization with MBP and adjuvants (McCombe et al., 1996a) , the model used in the present study. We now show that CsA treatment decreases the enrichment of V 8.2 + cells in the apoptotic CD5 + and apoptotic TCR + lymphocyte populations (Fig. 3) . 
Discussion
We assessed the effects of CsA treatment on the clinical course of MBP-EAE in Lewis rats. Salinetreated rats treated followed the usual clinical course of MBP-EAE (Pender, 1988) . Treatment with high doses of CsA (16 and 32 mg/kg) caused suppression of the expected first episode of disease, with clinical signs of disease developing after treatment was ceased. Previously, CsA (50 mg/kg) has been shown to suppress EAE induced by inoculation of rats, guinea pigs and monkeys with bovine spinal cord, although some animals developed disease after treatment was ceased (Bolton et al., 1982) . Treatment with CsA 4 mg/kg delayed the onset of the disease. Treatment with CsA 8 mg/kg delayed the onset of disease, increased the frequency of second episodes and resulted in 50% of rats having a third episode or following a chronic persistent course. This effect is similar to the effects of low-dose CsA treatment of EAE induced by inoculation with guinea pig spinal cord (Polman et al., 1988; Pender et al., 1990) and of experimental autoimmune neuritis (EAN) induced by inoculation with purified myelin (McCombe et al., 1990) . However, the dose of CsA (8 mg/kg) required to cause relapses of MBP-EAE was higher than that (4 mg/kg) required to produce relapses of EAE induced with whole spinal cord.
It is likely that the immunosuppressive actions of CsA (Hess et al., 1988) contribute to the suppression of signs of EAE. However, the ability of CsA to decrease blood-brain barrier permeability (Paul and Bolton, 1995) and the neuroprotective capacity of immunophilins (Sabatini et al., 1997) could also play a role. In earlier studies, Bolton et al. (1982) found that treatment with CsA 50 mg/kg caused a reduction in inflammation in the spinal cord of guinea pigs with EAE. In MBP-EAE, we now show that a single high dose of CsA (32 mg/kg) caused a decline in the percentage of TCR + cells in the spinal cord inflammatory infiltrate. This decline in the percentage of T cells in the spinal cord could result from decreased entry of cells to the CNS or increased removal from the CNS.
To determine whether CsA treatment caused increased elimination of cells, we measured apoptosis. During spontaneous recovery from MBP-EAE, there is apoptosis of T cells (Pender et al., 1991 and Pender et al., 1992; Schmied et al., 1993) and macrophages/microglia in the CNS (Nguyen et al., 1994; White et al., 1998a) . There is selective apoptosis of V 8.2 + MBP-reactive T cells (Tabi et al., 1994 and Tabi et al., 1995; McCombe et al., 1996a) , which may be due to CD95-mediated antigen-specific activation-induced apoptosis (White et al., 1998b) . Apoptosis of other cells in the CNS in EAE may be due to non-antigen-specific processes such as withdrawal of growth factors or the effects of endogenous corticosteroids (Pender et al., 1992; Nguyen et al., 1994) . We now show that apoptosis of inflammatory cells in the spinal cord in MBP-EAE is increased 16 h after treatment with CsA. The percentages of CD5 + cells and TCR + cells that were apoptotic were increased. There was no increase in apoptosis of V 8.2 + T cells, the predominant encephalitogenic T cells in this form of EAE (Imrich et al., 1995) . CsA treatment abrogated the selective apoptosis of V 8.2 + cells. We suggest that this indicates that CsA treatment leads to an increase in non-antigen-specific T cell apoptosis at the same time as decreasing antigen-specific activation-induced apoptosis of encephalitogenic T cells.
The observed increase in total T cell apoptosis could be due to effects of CsA on non-antigen-specific apoptosis, for example by suppression of production of cytokines such as IL-2 that are necessary for cell survival. Another mechanism for increased T cell apoptosis is suggested by the finding that CsA can enhance transforming growth factor mediated apoptosis of lymphocytes (Andjelic et al., 1997) . Our observation that CsA impairs the selective apoptosis of V 8.2 + T cells in the CNS may be explained by the known ability of CsA to reduce activation-induced apoptosis (Shi et al., 1989) , by inhibiting the expression of Fas ligand (Brunner et al., 1996; Latinis et al., 1997) . However, in the present study, we did not find a decline in expression of Fas or Fas ligand.
Low-dose CsA may cause relapses of disease by suppressing a mechanism that normally prevents further episodes of disease. We have previously shown that corticosteroid treatment of MBP-EAE increases total T cell apoptosis but reduces apoptosis of V 8.2 + cells in the CNS, and leads to relapses of EAE (McCombe et al., 1996b; Nguyen et al., 1997) . We therefore considered the possibility that CsA might induce relapses of disease by inhibiting the apoptosis of encephalitogenic T cells in the CNS. However, although we found that CsA treatment decreases the selective apoptosis of V 8.2 + cells, there was no decline in the percentage of V 8.2 + cells that were apoptotic. Another possible means by which CsA treatment could lead to relapses of EAE is by impairment of production of downregulatory cytokines. One possibility is IL-10 which is present in lower amounts in the spinal cord of DA rats, which follow a chronic course of MBP-EAE, compared to Lewis rats which have an acute course of disease (Diab et al., 1997) . Further studies are required to determine whether alteration of cytokine production is related to the production of relapses in the present model of relapsing MBP-EAE. In conclusion, the present study presents a model of chronic relapsing MBP-EAE in Lewis rats. It also shows that T cell apoptosis in the CNS in EAE can be modulated by the action of CsA.
